v3.26.3
Commitments and Contingencies - Clinical Trial Agreements (Details) - USD ($)
1 Months Ended
Sep. 30, 2026
Jul. 07, 2026
May 24, 2026
Oct. 31, 2024
Phase II Clinical Trial for Mpox        
Commitments and Contingencies        
Clinical trial expenses incurred       $ 1,632,000
Mpox clinical trial balance paid       794,000
Mpox clinical trial balance unpaid       838,000
Unpaid balance related to clinical trial expenses       226,000
Unpaid balance related to clinical trial fee payable       306,000
Unpaid balance related to clinical trial CRO fee payable       306,000
Estimated total additional cost       $ 734,000
Phase II Clinical Trial for Mpox | Maximum        
Commitments and Contingencies        
Percentage of management fees       30.00%
Phase II Clinical Trial for Ebola        
Commitments and Contingencies        
Clinical trial expenses incurred   $ 2,712,000    
Clinical trial expenses paid $ 1,658,000      
Mpox clinical trial balance unpaid   1,054,000    
Unpaid balance related to clinical trial expenses   279,000    
Unpaid balance related to clinical trial fee payable   388,000    
Unpaid balance related to clinical trial CRO fee payable   387,000    
Estimated total additional cost   $ 872,000    
Phase II Clinical Trial for Ebola | Maximum        
Commitments and Contingencies        
Percentage of management fees     20.00%